DK0978282T3 - Sublingualt præparat indeholdende apomorphin til diagnosticering af funktionel impotens - Google Patents

Sublingualt præparat indeholdende apomorphin til diagnosticering af funktionel impotens

Info

Publication number
DK0978282T3
DK0978282T3 DK99121684T DK99121684T DK0978282T3 DK 0978282 T3 DK0978282 T3 DK 0978282T3 DK 99121684 T DK99121684 T DK 99121684T DK 99121684 T DK99121684 T DK 99121684T DK 0978282 T3 DK0978282 T3 DK 0978282T3
Authority
DK
Denmark
Prior art keywords
diagnosis
preparation containing
containing apomorphine
functional impotence
sublingual preparation
Prior art date
Application number
DK99121684T
Other languages
English (en)
Inventor
Ragab El-Rashidy
Alvaro Morales
Jeremy P W Heaton
Michael A Adams
Original Assignee
Pentech Pharmaceuticals Inc
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22868404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0978282(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pentech Pharmaceuticals Inc, Univ Kingston filed Critical Pentech Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0978282T3 publication Critical patent/DK0978282T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
DK99121684T 1994-04-22 1995-04-21 Sublingualt præparat indeholdende apomorphin til diagnosticering af funktionel impotens DK0978282T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23125094A 1994-04-22 1994-04-22
EP95916467A EP0758895B1 (en) 1994-04-22 1995-04-21 Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
DK0978282T3 true DK0978282T3 (da) 2006-04-10

Family

ID=22868404

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99121684T DK0978282T3 (da) 1994-04-22 1995-04-21 Sublingualt præparat indeholdende apomorphin til diagnosticering af funktionel impotens
DK95916467T DK0758895T3 (da) 1994-04-22 1995-04-21 Sublinguale dosisformer indeholdende apomorphin til anvendelse ved behandling af erektil dysfunktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK95916467T DK0758895T3 (da) 1994-04-22 1995-04-21 Sublinguale dosisformer indeholdende apomorphin til anvendelse ved behandling af erektil dysfunktion

Country Status (16)

Country Link
US (3) US5770606A (da)
EP (2) EP0978282B1 (da)
JP (1) JP3310982B2 (da)
KR (1) KR100374924B1 (da)
AT (2) ATE189121T1 (da)
AU (1) AU703608B2 (da)
CA (1) CA2188385C (da)
DE (3) DE10199068I2 (da)
DK (2) DK0978282T3 (da)
ES (2) ES2256999T3 (da)
GR (1) GR3033084T3 (da)
HK (2) HK1025742A1 (da)
LU (1) LU90856I2 (da)
NL (1) NL300072I1 (da)
PT (1) PT758895E (da)
WO (1) WO1995028930A1 (da)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU751565B2 (en) * 1995-06-13 2002-08-22 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
BR9809848A (pt) * 1997-05-19 2000-06-27 Zonagen Inc Composição
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
KR20010021625A (ko) 1997-07-09 2001-03-15 추후보정 개선된 남성발기 기능장애 치료방법 및 그 조성물
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU751182B2 (en) * 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
AU5403499A (en) 1998-08-26 2000-03-21 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7577475B2 (en) * 1999-04-16 2009-08-18 Cardiocom System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
NZ517038A (en) * 1999-09-03 2003-04-29 Lilly Co Eli Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
CZ20023637A3 (cs) * 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
FR2813193B1 (fr) * 2000-08-25 2003-08-15 Pelvipharm Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JP2004513899A (ja) 2000-11-15 2004-05-13 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 抗鬱薬誘発性的機能不全のアポモルヒネによる治療
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1224933A1 (en) * 2001-01-19 2002-07-24 Sanofi-Synthelabo New combination of active ingredients containing alfuzosine and apomorphine
CA2435546A1 (en) * 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
WO2003066029A2 (en) * 2002-02-07 2003-08-14 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
EP1496915A1 (en) * 2002-03-19 2005-01-19 Brain 'N' Beyond Biotech Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
MXPA04011875A (es) * 2002-05-31 2005-03-31 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para liberacion sostenida de buprenorfina.
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
MXPA05010450A (es) 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
ME00320B (me) * 2003-06-17 2011-05-10 Janssen Pharmaceutica Nv Supstituisani spirobenzazepini
WO2007044976A2 (en) 2005-10-12 2007-04-19 Unimed Pharmaceuticals, Llc Improved testosterone gel and method of use
CA2637838A1 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
CN102480958B (zh) 2009-06-12 2015-08-19 Cynapsus疗法有限公司 舌下阿扑吗啡
KR101946774B1 (ko) 2010-12-16 2019-02-11 선오비온 파마슈티컬스 인코포레이티드 설하 필름
MX2016006087A (es) * 2013-11-11 2016-08-12 Impax Laboratories Inc Formulaciones de desintegracion rapida y metodos de uso.
WO2015191931A1 (en) * 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine

Also Published As

Publication number Publication date
US5985889A (en) 1999-11-16
EP0978282B1 (en) 2005-12-14
ES2143049T3 (es) 2000-05-01
DK0758895T3 (da) 2000-06-13
EP0758895B1 (en) 2000-01-26
NL300072I1 (nl) 2002-02-01
US6200983B1 (en) 2001-03-13
HK1025742A1 (en) 2000-11-24
DE10199068I2 (de) 2004-05-06
DE69534693D1 (de) 2006-01-19
ATE312609T1 (de) 2005-12-15
AU2295895A (en) 1995-11-16
WO1995028930A1 (en) 1995-11-02
AU703608B2 (en) 1999-03-25
ATE189121T1 (de) 2000-02-15
DE69514794T2 (de) 2000-07-27
EP0758895A1 (en) 1997-02-26
CA2188385C (en) 2000-07-11
DE69534693T2 (de) 2006-08-31
DE10199068I1 (de) 2003-06-05
LU90856I2 (fr) 2002-01-24
EP0978282A3 (en) 2000-06-07
EP0978282A2 (en) 2000-02-09
PT758895E (pt) 2000-05-31
JP3310982B2 (ja) 2002-08-05
HK1014239A1 (en) 1999-09-24
KR970702041A (ko) 1997-05-13
EP0758895A4 (en) 1997-04-09
KR100374924B1 (ko) 2003-07-22
DE69514794D1 (de) 2000-03-02
ES2256999T3 (es) 2006-07-16
US5770606A (en) 1998-06-23
CA2188385A1 (en) 1995-11-02
GR3033084T3 (en) 2000-08-31
JPH09512273A (ja) 1997-12-09

Similar Documents

Publication Publication Date Title
DK0978282T3 (da) Sublingualt præparat indeholdende apomorphin til diagnosticering af funktionel impotens
ATE12042T1 (de) Aminosaeurederivate und ihre therapeutische verwendung.
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
ATE69239T1 (de) Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung.
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
AU575306B2 (en) Proline derivatives
ES2105362T3 (es) Nuevos derivados de acidos quinolon- y naftiridoncarboxilicos.
FI945975A (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
FR2381762A1 (fr) Dibenzodiazepines utilisables comme antischizophreniques
ES8706654A1 (es) Un procedimiento para la preparacion de nuevos derivados de benzotiazina
WO1999014241A3 (en) Compositions and methods for the treatment of immune related diseases
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
ATE93863T1 (de) Enzym-hemmende aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung.
DE69104220D1 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
DE58906606D1 (de) Optisch aktive Rhodiumkomplexe von 3,4-Bis(diarylphosphino)-pyrrolidinen und ihre Verwendung zur Herstellung von Phosphinothricin durch asymmetrische Hydrierung.
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
DE59007216D1 (de) Verfahren zur Herstellung von Clausenamid und Neoclausenamid und deren Derivate.
DE68923836D1 (de) Verfahren zur Herstellung von wässrigen Zusammensetzungen von Silikonelastomeren.
ES8501380A1 (es) Un procedimiento para preparar l-tiazolidin-4-carboxilato de zinc
FR2377446A1 (fr) Composition antimicrobienne de nettoyage de la peau
TR200101425T2 (tr) IL-5 inhibe edici 6-azaurasil türevleri
FR2431861A1 (fr) Composition destinee a l'hygiene buccale
FR2375188A1 (fr) Pour : nitro-amines utilisables comme composantes de diazotation
ATE40693T1 (de) Neue thyroninderivate.
ES2071723T3 (es) Bencilseleniobenzoamidas de aminopiridinas y picolilaminas.